# Abbott Separates Nutrition Business for Growth

> Abbott plans to spin off its nutrition division as an independent company by end of 2027 to boost growth and focus.
- Title: Abbott Separates Nutrition Business for Growth | Shortify
- Summary: Abbott plans to spin off its nutrition division as an independent company by end of 2027 to boost growth and focus. Abbott will separate its nutrition…
- Keywords: abbott, nutrition, separation, spinoff, healthcare, diagnostics, medical devices, pharmaceuticals, q3 2026, earnings call, finance, money
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/21/abbott-abt-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-21T18:22:51+00:00
- Read time: 2 min
- Topics: abbott, nutrition, separation, spinoff, healthcare, diagnostics, medical devices, pharmaceuticals, q3 2026, earnings call, finance, money
## Abbott Announces Nutrition Spinoff
Abbott plans to separate its nutrition business into an independent, publicly traded company by end of 2027.
## Nutrition Business Details
The nutrition division has $8.5 billion in annual sales, 16,000 employees, and 14 manufacturing sites globally.
## Daniel Salvadori Named CEO
Daniel Salvadori, Executive Vice President of Established Pharmaceuticals and Nutrition, will lead the new company.
## Q3 2026 Financial Results
Total reported sales increased 14.5% to $13.013 billion, with adjusted diluted EPS at $1.42.
## Nutrition Segment Growth
U.S. pediatric nutrition grew 11.0% year over year following WIC contract wins and regained market leadership.
## Diagnostics Revenue Surge
Diagnostics revenue increased 46.7% on a reported basis, driven by cancer diagnostics and precision oncology.
## Medical Devices Growth
Medical devices revenue grew 7.8% on a comparable basis, led by electrophysiology and rhythm management.
## Electrophysiology Performance
Electrophysiology revenue grew 15.0% on a reported basis with full U.S. launch of Volt PFA catheter.
## Diabetes Care Progress
Diabetes care revenue grew 6.7% as Libre adoption continues globally.
## Full-Year Guidance
Full-year comparable sales growth expected at 6.0%, with adjusted EPS guidance of $5.50 to $5.55.
## Separation Benefits
The separation is expected to improve Abbott's portfolio growth by 50 to 100 basis points.
## Rhythm Management Growth
Rhythm management grew 9.7% reported growth driven by increased adoption of AVEIR leadless pacemaker.
## R&D Investment
Adjusted R&D investment at $892 million, representing 6.9% of sales for innovation pipeline.
## EPD Growth in Emerging Markets
Key emerging markets EPD growth at 10.9% on a comparable basis, led by India and Latin America.
## EP Headwinds
EP faces short-term headwinds from LAA market dynamics, with orders slowing as accounts await new Amulet 360 device.
## Diabetes Pricing Pressure
International diabetes markets face pricing pressure that may mute volume growth in the near term.
## Key takeaway

Abbott will separate its nutrition business into an independent company by end of 2027 to accelerate growth and improve margins.